Mesenchymal stem cells and inflammatory lung diseases

Smita Iyer, M. Rojas

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Mesenchymal stem cells (MSCs) are emerging as a therapeutic modality in various inflammatory disease states. A number of ongoing randomized Phase I/II clinical trials are evaluating the effects of allogeneic MSC infusion in patients with multiple sclerosis, graft-versus-host disease, Crohn's disease, and severe chronic myocardial ischemia. MSCs are also being considered as a potential therapy in patients with inflammatory lung diseases. Several studies, including our own, have demonstrated compelling benefits from the administration of MSCs in animal models of lung injury. These studies are leading to growing interest in the therapeutic use of MSCs in inflammatory lung diseases. In this Review, we describe how the immunoregulatory effects of MSCs can confer substantial protection in the setting of lung diseases such as acute lung injury, chronic obstructive pulmonary disease, asthma, and pulmonary hypertension. We also address potential pitfalls related to the therapeutic use of MSCs in fibrotic lung diseases such as idiopathic pulmonary fibrosis. In addition, we identify emerging areas for MSC- based therapies in modulating oxidative stress and in attenuating inflammation in alcohol-related acute lung injury.

Original languageEnglish (US)
Pages (from-to)5-16
Number of pages12
JournalPanminerva Medica
Volume51
Issue number1
StatePublished - Mar 1 2009
Externally publishedYes

Fingerprint

Mesenchymal Stromal Cells
Lung Diseases
Acute Lung Injury
Therapeutic Uses
Idiopathic Pulmonary Fibrosis
Phase II Clinical Trials
Clinical Trials, Phase I
Lung Injury
Graft vs Host Disease
Cell- and Tissue-Based Therapy
Pulmonary Hypertension
Crohn Disease
Chronic Obstructive Pulmonary Disease
Multiple Sclerosis
Myocardial Ischemia
Oxidative Stress
Asthma
Randomized Controlled Trials
Animal Models
Alcohols

Keywords

  • Acute lung injury
  • Cytokines
  • Mesenchymal stem cells
  • Oxidative stress

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Iyer, S., & Rojas, M. (2009). Mesenchymal stem cells and inflammatory lung diseases. Panminerva Medica, 51(1), 5-16.

Mesenchymal stem cells and inflammatory lung diseases. / Iyer, Smita; Rojas, M.

In: Panminerva Medica, Vol. 51, No. 1, 01.03.2009, p. 5-16.

Research output: Contribution to journalArticle

Iyer, S & Rojas, M 2009, 'Mesenchymal stem cells and inflammatory lung diseases', Panminerva Medica, vol. 51, no. 1, pp. 5-16.
Iyer, Smita ; Rojas, M. / Mesenchymal stem cells and inflammatory lung diseases. In: Panminerva Medica. 2009 ; Vol. 51, No. 1. pp. 5-16.
@article{4e23c1b0d73c48619eeb0d64d8d643ee,
title = "Mesenchymal stem cells and inflammatory lung diseases",
abstract = "Mesenchymal stem cells (MSCs) are emerging as a therapeutic modality in various inflammatory disease states. A number of ongoing randomized Phase I/II clinical trials are evaluating the effects of allogeneic MSC infusion in patients with multiple sclerosis, graft-versus-host disease, Crohn's disease, and severe chronic myocardial ischemia. MSCs are also being considered as a potential therapy in patients with inflammatory lung diseases. Several studies, including our own, have demonstrated compelling benefits from the administration of MSCs in animal models of lung injury. These studies are leading to growing interest in the therapeutic use of MSCs in inflammatory lung diseases. In this Review, we describe how the immunoregulatory effects of MSCs can confer substantial protection in the setting of lung diseases such as acute lung injury, chronic obstructive pulmonary disease, asthma, and pulmonary hypertension. We also address potential pitfalls related to the therapeutic use of MSCs in fibrotic lung diseases such as idiopathic pulmonary fibrosis. In addition, we identify emerging areas for MSC- based therapies in modulating oxidative stress and in attenuating inflammation in alcohol-related acute lung injury.",
keywords = "Acute lung injury, Cytokines, Mesenchymal stem cells, Oxidative stress",
author = "Smita Iyer and M. Rojas",
year = "2009",
month = "3",
day = "1",
language = "English (US)",
volume = "51",
pages = "5--16",
journal = "Panminerva Medica",
issn = "0031-0808",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Mesenchymal stem cells and inflammatory lung diseases

AU - Iyer, Smita

AU - Rojas, M.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Mesenchymal stem cells (MSCs) are emerging as a therapeutic modality in various inflammatory disease states. A number of ongoing randomized Phase I/II clinical trials are evaluating the effects of allogeneic MSC infusion in patients with multiple sclerosis, graft-versus-host disease, Crohn's disease, and severe chronic myocardial ischemia. MSCs are also being considered as a potential therapy in patients with inflammatory lung diseases. Several studies, including our own, have demonstrated compelling benefits from the administration of MSCs in animal models of lung injury. These studies are leading to growing interest in the therapeutic use of MSCs in inflammatory lung diseases. In this Review, we describe how the immunoregulatory effects of MSCs can confer substantial protection in the setting of lung diseases such as acute lung injury, chronic obstructive pulmonary disease, asthma, and pulmonary hypertension. We also address potential pitfalls related to the therapeutic use of MSCs in fibrotic lung diseases such as idiopathic pulmonary fibrosis. In addition, we identify emerging areas for MSC- based therapies in modulating oxidative stress and in attenuating inflammation in alcohol-related acute lung injury.

AB - Mesenchymal stem cells (MSCs) are emerging as a therapeutic modality in various inflammatory disease states. A number of ongoing randomized Phase I/II clinical trials are evaluating the effects of allogeneic MSC infusion in patients with multiple sclerosis, graft-versus-host disease, Crohn's disease, and severe chronic myocardial ischemia. MSCs are also being considered as a potential therapy in patients with inflammatory lung diseases. Several studies, including our own, have demonstrated compelling benefits from the administration of MSCs in animal models of lung injury. These studies are leading to growing interest in the therapeutic use of MSCs in inflammatory lung diseases. In this Review, we describe how the immunoregulatory effects of MSCs can confer substantial protection in the setting of lung diseases such as acute lung injury, chronic obstructive pulmonary disease, asthma, and pulmonary hypertension. We also address potential pitfalls related to the therapeutic use of MSCs in fibrotic lung diseases such as idiopathic pulmonary fibrosis. In addition, we identify emerging areas for MSC- based therapies in modulating oxidative stress and in attenuating inflammation in alcohol-related acute lung injury.

KW - Acute lung injury

KW - Cytokines

KW - Mesenchymal stem cells

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=67650136226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650136226&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 5

EP - 16

JO - Panminerva Medica

JF - Panminerva Medica

SN - 0031-0808

IS - 1

ER -